Article Sidebar
Published:
Oct 1, 2015DOI:
10.4314/tjpr.v14i5.9Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Antidiabetic Efficacy of Aqueous Fruit Extract of Amla (Emblica officinalis, Gaertn) in Streptozotocin-Induced Diabetes Mellitus in Male Rats
Abstract
Purpose: To investigate the antidiabetic potential of Emblica officinalis, Gaertn on diabetic rats.
Methods: The study investigated the anti-hyperglycemic potential of the aqueous fruit extract of amla (E. officianalis, for eleven weeks in streptozotocin-induced diabetic obese rats. The study utilized forty eight rats divided into four groups as follows. Untreated diabetic control (group 1) received 2 % gum acacia as vehicle; groups 2 and 3 were diabetic rats administered the fruit extract in 400 and 200 mg/kg doses, respectively; while group 4 (diabetic rats) received metformin (600 mg/kg) as reference drug. The parameters assessed weekly were body weight, as well as fasting blood glucose, cholesterol and triglyceride levels in venous blood.
Results: Both plant extract-treated groups showed significant (p ≤ 0.001) reduction in blood glucose levels in the fifth and sixth weeks compared to the metformin-treated group. Body weight significantly increased during the fourth, fifth and sixth weeks, being more pronounced in the extract-treated groups (272 ± 15.0 g and 227 ± 7.23 g for 200 and 400 mg/kg doses, respectively; the corresponding body weight for untreated diabetic control was 197 ± 9.83 g. Furthermore, both extract doses (200 and 400 mg/kg) produced significant decrease (p ≥ 0.05) in serum glucose (186 ± 15.5 mg/L and 146 ± 15.1 mg/L), cholesterol (143.6 ± 0.86 mg/L and 151.0 ± 0.77mg/L) and triglyceride (82.6 ± 0.51mg/dl and 84.8 ± 0.84 m/dl) levels, respectively, similar to the metformin treated group.
Conclusion: The anti-diabetic activity of the aqueous extract of E. officianalis used showed a better potential than metformin.
Keywords: Antidiabetic, Emblica officianalis fruit, Obesity, Glucose, Cholesterol, Triglycerides
